

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I

3966 LU/Pagediefl

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

www.uspto.gov
ATTORNEY DOCKET NUMBER

09/998,966

10/31/2001

Richard A. Shimkets

15966-55 CON-S2 (Cura-51

CONFIRMATION NO. 7979

FORMALITIES LETTER

OC00000007428926

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C. One Financial Center Boston, MA 02111

Date Mailed: 02/06/2002

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52 because:
 - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4")

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

Express Mail Label No.: EL)47114623US

Date of Deposit: July 3, 2002

Attorney Docket No. 15966-551CON S-2 (CURA-51CON S-2)

JUL 0 3 2002

THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Shimkets et al.

SERIAL NUMBER:

09/998,966

EXAMINER:

Not Yet Assigned

FILING DATE:

October 31, 2001

ART UNIT:

1646

FOR:

Novel Nucleic Acid Sequences Encoding Human Fibroblast Growth Factor-like

Polypeptides

Assistant Commissioner for Patents

Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified application are the following documents:

- 1. Response to Notice to File Corrected Application Papers (1 pg);
- 2. Copy of Notice to File Corrected Application Papers (1 pg);
- 3. Substitute Specification (123 pgs);
- 4. Statement in Support of Substitute Specification (1 pg);
- 5. Petition for Extension of Time;
- 6. Check No.13319 in the amount of \$920.00 to cover extension fee; and,
- 7. Return Postcard.

The Commissioner is hereby authorized to charge any fee that may be due, or to credit any overpayment, to Deposit Account No. 50-0311, Reference No. 15966-551CON-S2 (Cura 51CON-S2). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Cynthia A. Kozakiewicz, Reg. No. 42,764

Attorney for Applicants c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: July 3, 2002

30623

PATENT TRADEMARK OFFICE

Attorney Docket No. 15966-551CON S-2 (CURA-51CON S-2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Shimkets et al.

SERIAL NUMBER:

Express Mail Label No.: EI Date of Deposit: July 3, 2002

09/998,966

EXAMINER:

Not Yet Assigned

FILING DATE:

October 31, 2001

ART UNIT:

FOR:

Novel Nucleic Acid Sequences Encoding Human Fibroblast Growth Factor-like

Polypeptides

Assistant Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified application are the following documents:

- 1. Response to Notice to File Corrected Application Papers (1 pg);
- Copy of Notice to File Corrected Application Papers (1 pg); 2.
- Substitute Specification (123 pgs); 3.
- 4. Statement in Support of Substitute Specification (1 pg);
- 5. Petition for Extension of Time;
- Check No.13319 in the amount of \$920.00 to cover extension fee; and, 6.
- 7. Return Postcard.

* The Commissioner is hereby authorized to charge any fee that may be due, or to credit any overpayment, to Deposit Account No. 50-0311, Reference No. 15966-551CON-S2 (Cura 51CON-S2). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Cynthia A. Kozakiewicz, Reg. No. 42,764

Attorney for Applicants c/o MINTZ, LEVIN

One Financial Center Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: July 3, 2002

PATENT TRADEMARK OFFICE

Express Mail Label No.: EI

Date of Deposit: July 3, 2002

Attorney Docket No. 15966-551CON S-2 (CURA-51CON S-2)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Shimkets et al.

SERIAL NUMBER:

09/998,966

EXAMINER:

Not Yet Assigned

FILING DATE:

October 31, 2001

ART UNIT:

1646

FOR:

Novel Nucleic Acid Sequences Encoding Human Fibroblast Growth Factor-like

Polypeptides

Assistant Commissioner for Patents Washington, D.C. 20231

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

In response to the Notice To File Corrected Application Papers mailed February 6, 2002, 2002, Applicants submit herein a copy of the Notice to File Corrected Application Papers, Substitute Specification (123 pages); Statement in Support of Substitute Specification (1 page); and a three-month extension of time. This filing is in compliance with 37 C.F.R. §§ 1.121(b)(3), 1.125.

Please replace the previously filed specification with the attached substitute specification, pages 1-123.

The response is due on or before July 6, 2002. Although Applicants believe no fees are due with this filing, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 15966-551CON S-2 (CURA-51CON S-2).

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Cynthia A. Kozakiewiez, Reg. No. 42,764

Attorney for Applicants c/o MINTZ, LEVIN

One Financial Center Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: July 3, 2002

099**33**955.070302

Express Mail Label No.: El 114623US Date of Deposit: July 3, 2002

Attorney Docket No. 15966-551CON S-2 (CURA-51CON S-2)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Shimkets et al.

SERIAL NUMBER:

09/998,966

EXAMINER:

Not Yet Assigned

FILING DATE:

October 31, 2001

ART UNIT:

1646

FOR:

Novel Nucleic Acid Sequences Encoding Human Fibroblast Growth Factor-like

Polypeptides

Assistant Commissioner for Patents

Washington, D.C. 20231

STATEMENT IN SUPPORT OF SUBSTITUTE SPECIFICATION (37 CFR 1.125(b)(1))

Pursuant to 37 CFR 1.125(b)(1), I hereby state that the content of the substitute specification and the specification filed on October 31, 2001 are the same. Applicants hereby submit this substitute specification in response to the Notice to File Corrected Application Papers mailed on February 6, 2002, which specifically requested a substitute specification in compliance with 37 CFR 1.52. The correction of the margins is the only amendment made to the specification at this time. Thus, this submission includes no new matter.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-0311, Ref. No.15966-551CON S-2 (CURA-51CON S-2).

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Cynthia A. Kozakiewicz, Reg. No. 42,764

Attorney for Applicants c/o MINTZ, LEVIN
One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: July 3, 2002